H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.
Research Report
This article is issued on behalf of Treatment.com AI Inc. Is This AI Healthcare Stock Worth Being Overweight On?
Contributed Opinion 
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Mass. Biotech Receives FDA Approval
Research Report
CT Biotech Ready for Clinical Milestones
Research Report
Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial
Research Report
New Jersey Biotech Reports Positive Survival Data
Research Report
California Biotech's Target Price 200% Higher Than Current
Research Report
Target Price Raised on Biotech Co.
Research Report
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company. CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment
Research Report
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note. AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers.Revolutionizing Chronic Disease Treatment Through Regenerative Medicine
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential.Implanted Cell Device Reaches 5 Year Milestone
Research Report
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report. This article is issued on behalf of Sernova Corp. Is It Now Time To Buy This Biotech Stock?
Contributed Opinion Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows.
Co's. Cell Pouch Performs Well in Study
Research Report
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report. Trial Data Help Position Cell Pouch for Commercial Success
Research Report
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report. California Biotech Reports Positive QOL Improvements in Program
Research Report
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating. 
Streetwise Key Charts
